TheraCryf PLC
8EV
Company Profile
Business description
TheraCryf PLC is a clinical-stage biotechnology company focused on profitable segments in oncology and neuropsychiatry. The company's lead clinical asset, SFX-01 is a patented form of delivering sulforaphane, which could be used in the treatment of a number of cancers, neurodevelopmental disorders, and other diseases.
Contact
Congleton Road
Alderley Park
Nether AlderleyCheshireSK10 4TG
GBRT: +44 1625315090
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 March 2026
Employees
9
Stocks News & Analysis
stocks
Chart of the Week: The market may be underestimating Amcor’s long term potential
Our latest stock pitch.
stocks
Competitive pressures highlight need to lower costs for big 4 bank
Market reacts positively to results.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,079.40 | 38.00 | -0.42% |
| CAC 40 | 8,241.24 | 85.01 | 1.04% |
| DAX 40 | 24,381.46 | 293.40 | 1.22% |
| Dow JONES (US) | 48,279.37 | 351.41 | 0.73% |
| FTSE 100 | 9,911.42 | 11.82 | 0.12% |
| HKSE | 26,922.73 | 226.32 | 0.85% |
| NASDAQ | 23,380.77 | 87.53 | -0.37% |
| Nikkei 225 | 51,063.31 | 220.38 | 0.43% |
| NZX 50 Index | 13,671.73 | 67.18 | 0.49% |
| S&P 500 | 6,848.14 | 1.53 | 0.02% |
| S&P/ASX 200 | 8,799.50 | 36.50 | -0.41% |
| SSE Composite Index | 4,000.14 | 2.62 | -0.07% |